SCHEMBL6087310

SCHEMBL6087310

Cc1ccc2nc(-c3c[nH]nc3-c3ccc(NC(=O)c4csc(-c5ccncc5)n4)cc3)oc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
NPC1 O15118 1/20 0.48
ALDH1A1 P00352 1/20 0.48
RAB9A P51151 1/20 0.48
LMNA P02545 2/20 0.48
MAPK1 P28482 2/20 0.46
BAZ1A Q9NRL2 1/20 0.45
POLB P06746 3/20 0.45
ROCK1 Q13464 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CETP P11597 1/20 0.44
AGPAT2 O15120 1/20 0.44
ROCK2 O75116 2/20 0.44
TLR7 Q9NYK1 1/20 0.44
TP53 P04637 1/20 0.44
KDM4E B2RXH2 1/20 0.43
IRAK4 Q9NWZ3 1/20 0.42
TDP1 Q9NUW8 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085752 0.84 MAPT (0.48) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL6085746 0.81 AGPAT2 (0.53) MAPTMEN1KMT2ANPC1ALDH1A1
SCHEMBL6086313 0.80 CETP (0.56) MAPTMEN1KMT2ANPC1ALDH1A1
SCHEMBL6085716 0.79 MAPT (0.55) MAPTMEN1KMT2ANPC1ALDH1A1
SCHEMBL6086965 0.78 MAPT (0.61) MAPTMEN1KMT2ANPC1ALDH1A1
SCHEMBL6084581 0.78 MAPT (0.54) MAPTMEN1KMT2ANPC1ALDH1A1
SCHEMBL6085189 0.78 MAPT (0.67) MAPTMEN1KMT2ANPC1ALDH1A1
SCHEMBL6085536 0.78 MAPT (0.49) MAPTMEN1KMT2ANPC1ALDH1A1
SCHEMBL6085906 0.77 MAPT (0.53) MAPTMEN1KMT2ANPC1ALDH1A1
SCHEMBL6085303 0.76 MAPT (0.50) MAPTMEN1KMT2ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 MAPT 801/4885MEN1 2891/4885KMT2A 921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.